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Summary
 
We have identified platelet glycoprotein (GP) Ib
 
a
 
 as a counterreceptor for P-selectin. GP Ib
 
a
 
is a component of the GP Ib-IX-V complex, which mediates platelet adhesion to subendothe-
lium at sites of injury. Cells expressing P-selectin adhered to immobilized GP Ib
 
a
 
, and GP
 
Ib
 
a
 
–
 
expressing cells adhered to and rolled on P-selectin and on histamine-stimulated endothe-
lium in a P-selectin–dependent manner. In like manner, platelets rolled on activated endothe-
lium, a phenomenon inhibited by antibodies to both P-selectin and GP Ib
 
a
 
. Unlike the P-selec-
tin interaction with its leukocyte ligand, PSGL-1 (P-selectin glycoprotein ligand 1), the
interaction with GP Ib
 
a
 
 required neither calcium nor carbohydrate core-2 branching or
 
a
 
(1,3)-fucosylation. The interaction was inhibited by sulfated proteoglycans and by antibodies
against GP Ib
 
a
 
, including one directed at a tyrosine-sulfated region of the polypeptide. Thus,
the GP Ib-IX-V complex mediates platelet attachment to both subendothelium and activated
endothelium.
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D
 
uring inflammatory processes, endothelial selectins
mediate the initial interaction of leukocytes with en-
dothelium as the leukocytes make their way from the
bloodstream into the tissues. The interaction of the selec-
tins with leukocyte mucins, in particular a protein called
P-selectin glycoprotein ligand 1 (PSGL-1),
 
1
 
 is characterized
by having rapid on and off rates, allowing the leukocytes in
the flowing blood to roll along the endothelium. These
leukocytes then undergo a tighter interaction with the ves-
sel wall mediated by 
 
b
 
2 integrins on the leukocytes and re-
ceptors of the Ig superfamily on the endothelial cells (1).
P-selectin is the first selectin to be expressed on the endo-
thelial surface in response to inflammatory stimuli such as
thrombin and histamine, translocating from the membranes
of storage granules (the Weibel-Palade bodies) to the
plasma membrane within seconds. P-selectin and the other
selectins, E- and L-selectin, are type I transmembrane pro-
teins, each having an NH
 
2
 
-terminal C-type lectin domain
followed by an epidermal growth factor domain and a se-
ries of short complement repeats that separate the lectin do-
main from the plasma membrane (2). The P-selectin inter-
action with PSGL-1 requires a number of posttranslational
modifications in the latter molecule, including a branched,
fucosylated structure on its O-linked carbohydrate side
chains (3) and sulfated tyrosine residues within a cluster of
acidic residues at its NH
 
2
 
 terminus (4–7).
Like leukocytes, unactivated platelets can roll on the sur-
face of inflamed endothelium, in a process dependent on
endothelial selectins (8). The process is independent of
platelet selectins, as platelets from mice lacking P- and E-selec-
tin roll as efficiently as platelets from normal mice (9). Un-
like the interaction of the selectins with leukocytes, their
interaction with platelets does not require fucosylation of
the ligand, as no difference was observed between platelets
from mice lacking both 
 
a
 
(1,3)-fucosyl transferases (FucTs),
FucT IV and FucT VII, and those of normal mice. These
studies were the first to demonstrate that unactivated plate-
lets interact with endothelial cells, which are generally con-
sidered nonthrombogenic. In marked contrast, it is well
 
1
 
Abbreviations used in this paper:
 
 ANOVA, analysis of variance; CHO, Chi-
nese hamster ovary; FucT, fucosyl transferase; GP, glycoprotein; HU-
VECs, human umbilical vein endothelial cells; PSGL-1, P-selectin glyco-
protein ligand 1.  
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known that when the endothelium is removed, platelets
interact rapidly with the exposed matrix, initially through
the platelet glycoprotein (GP) Ib-IX-V complex and sub-
endothelial von Willebrand factor (10). The GP Ib-IX-V
complex comprises four polypeptides, GP Ib
 
a
 
, GP Ib
 
b
 
,
GP IX, and GP V, and can support the rolling of platelets
(11) and transfected cells (12, 13) on immobilized von
Willebrand factor under flow, a process similar to the roll-
ing interaction of platelets on inflamed endothelium, albeit
at much higher shear rates. GP Ib
 
a
 
 contains the von Wille-
brand factor–binding site and, like PSGL-1, it is a sialomu-
cin with a cluster of O-linked carbohydrates separating
the NH
 
2
 
-terminal ligand-binding region from the plasma
membrane. In addition, it contains a region rich in anionic
amino acids with sulfated tyrosines necessary for optimal
ligand binding (14–16). A further parallel between GP Ib
 
a
 
and PSGL-1 is the site of synthesis of their ligands: von
Willebrand factor and P-selectin are synthesized and stored
only in the Weibel-Palade bodies of endothelial cells and
the 
 
a
 
-granules of megakaryocytes and platelets. Given
these similarities between the two molecules and the high
surface density of GP Ib
 
a
 
 on the platelet surface (25,000–
50,000 copies per platelet), we sought to determine if the
GP Ib-IX-V complex might constitute a P-selectin coun-
terreceptor.
 
Materials and Methods
 
Antibodies.
 
Antibodies against P-selectin included affinity-
purified polyclonal antiserum produced in rabbits immunized
with P-selectin purified from platelet lysates (17) and the mAb
WAPS 12.2 (Zymed Labs., Inc.). Anti-GP Ib
 
a
 
 mAbs used were:
WM23 and AK3, both of which bind within the mucin-like
macroglycopeptide (18); SZ2, which recognizes an epitope
within the anionic/sulfated tyrosine region of GP Ib
 
a
 
 bounded
by residues Tyr276 and Glu282 (16); and AK2 (RDI Research
Diagnostics), which binds within the GP Ib
 
a
 
 NH
 
2 
 
terminus and
inhibits ristocetin- and botrocetin-induced von Willebrand factor
binding (16). Two von Willebrand factor mAbs were used in
these studies: 6G1, which inhibits the von Willebrand factor–GP
Ib
 
a
 
 interaction (our unpublished data), and 2C9, which does not
inhibit the binding of von Willebrand factor to GP Ib
 
a
 
 and was
used as a control mAb (18). HECA-452 is a rat mAb (IgM) that
recognizes a FucT VII–dependent carbohydrate (19, 20).
 
Glycocalicin Purification.
 
Glycocalicin was isolated from out-
dated human platelets by a method modified from that of Hess et al.
(21). Erythrocyte-free platelets were isolated from 10 liters of
outdated platelet-rich plasma (obtained from the Blood Transfu-
sion Centre, Cambridge, England) by centrifugation and washed
with buffer A (13 mM Na
 
3 
 
citrate, 120 mM NaCl, and 30 mM
glucose, pH 7.0). After another centrifugation, the platelet pellet
was suspended in 500 ml of buffer B (10 mM Tris/HCl, 150 mM
NaCl, and 2 mM CaCl
 
2
 
, pH 7.4) and sonicated. The resultant
suspension was then incubated at 37
 
8
 
C for 30 min to allow the
calpain released from the platelets during sonication to cleave
membrane-bound GP Ib
 
a
 
, releasing glycocalicin. After ultracen-
trifugation to remove cell components, the glycocalicin-containing
supernatant was applied to a wheat germ Sepharose 4B column.
Bound crude glycocalicin was eluted with 2.5% 
 
N
 
-acetyl-
 
d
 
-glu-
cosamine and 20 mM Tris/HCl, pH 7.4. Further purification by
ion exchange chromatography (on Q-Sepharose Fast-flow col-
umn; Pharmacia) was needed to remove residual contaminants.
Glycocalicin was eluted with a linear salt gradient of 0–0.7 M
NaCl in 20 mM Tris/HCl, pH 7.4.
 
Cell Lines.
 
Chinese hamster ovary (CHO) cells expressing a
phosphatidylinositol glycan–linked form of P-selectin were a gift
from Dr. C. Wayne Smith (Baylor College of Medicine, Hous-
ton, TX) (22). These cells were grown in medium comprising
equal parts DMEM and F12 medium (GIBCO BRL) supplemented
with 5% fetal bovine serum, 2 mM 
 
l
 
-glutamine, 100 U/ml peni-
cillin, and 100 U/ml streptomycin. CHO and L cells expressing
the GP Ib-IX-V complex and its components have been de-
scribed previously (23). In brief, CHO 
 
ab
 
IX cells express GP
Ib
 
a
 
, GP Ib
 
b
 
, and GP IX, the three polypeptides that are mini-
mally required for efficient cell surface expression of GP Ib
 
a
 
. L
 
ab
 
IXV cells additionally express GP V, and CHO and L 
 
b
 
IX
cells express GP Ib
 
b
 
 and GP IX but lack GP Ib
 
a
 
 and GP V. The
conditions for their growth have been described (23, 24).
 
Flow Cytometry.
 
Before each experiment involving cells that
express GP Ib
 
a
 
, the surface level of this polypeptide was first de-
termined by flow cytometry using AK2 as previously described
(25). In brief, cells grown in a monolayer were detached with
0.54 mM EDTA, washed with PBS, and resuspended in PBS
containing 1% BSA. The cells were then incubated with AK2 (1
 
m
 
g/ml) for 60 min at room temperature. After being washed to
remove unbound antibody, the cells were incubated with an
FITC-conjugated rabbit anti–mouse secondary antibody (Zymed
Labs., Inc.) for 30 min at room temperature. The cells were then
analyzed on a FACScan™ flow cytometer (Becton Dickinson)
stimulating with laser light at 488 nm and collecting light emitted
at 
 
.
 
520 nm.
 
Transfections.
 
To induce core-2 branching and 
 
a
 
(1,3)-fucosy-
lation of the GP Ib
 
a
 
 carbohydrates in CHO cells, the cells were
cotransfected with plasmids containing cDNAs encoding C2GnT
(core 2 
 
b
 
(1,6)-
 
N
 
-acetylglucosaminyltransferase), (pCDNA1/
C2GnT, a gift from Dr. Minoru Fukuda, La Jolla Cancer Re-
search Foundation, La Jolla, CA) and FucT VII (provided for
these studies by Dr. John Lowe, Howard Hughes Medical Insti-
tute, University of Michigan, Ann Arbor, MI) using a modified
SRa vector containing a hygromycin resistance marker (19).
Transfections were by liposome-mediated DNA delivery (Lipo-
fectAMINE; GIBCO BRL). A total of 1 
 
m
 
g of plasmid was used
in each transfection, with the FucT VII plasmid transfected either
alone or as an equal mixture with the plasmid containing the
C2GnT cDNA. The cells were selected by growth in hygromy-
cin-containing medium, for which a resistance marker is con-
tained in the FucT VII plasmid. FucT VII expression was evalu-
ated by flow cytometry with the antibody HECA-452, which
recognizes a FucT VII–dependent epitope. Labeling and analysis
were as described above for GP Ib
 
a
 
, except that an FITC-conju-
gated rabbit anti–rat antibody (Zymed Labs., Inc.) was used to la-
bel cell-bound HECA-452.
 
CHO-P Adhesion to Glycocalicin.
 
The wells of 96-well micro-
titer plates (Nunc Immulon, Inc.) were coated with 50 
 
m
 
l of pu-
rified glycocalicin (20 
 
m
 
g/ml in PBS, pH 7.4) for 2 h at room
temperature. The wells were rinsed four times over 20 min with
DMEM containing 1% BSA. CHO cells and CHO cells expressing
P-selectin (CHO-P) were detached from culture dishes using 5 ml
of 0.54 mM EDTA in PBS, washed once in PBS and once in
DMEM, and then incubated at 37
 
8
 
C for 30 min in DMEM con-
taining 0.5 mCi of 
 
51
 
Cr per 10
 
7
 
 cells. Cells were then washed three
times by centrifugation and resuspension and then resuspended to
a density of 2 
 
3 
 
10
 
6
 
 cells/ml in DMEM containing 1.0% BSA and 
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preincubated at room temperature for 15 min with either 10 mM
Tris/HCl, pH 7.4, in 0.15 M NaCl (TS buffer) alone or with TS
buffer containing appropriate amounts of sulfated glycans or
other blocking reagents. Aliquots of 0.1 ml of the cell suspension
were incubated at room temperature in four replicate microtiter
wells for 15 min. The media and nonadherent cells were then re-
moved, and the wells were rinsed three times with DMEM contain-
ing 1% BSA. 
 
51
 
Cr-labeled cells that remained adherent to the
wells were lysed in a solution containing 1% Triton X-100, and
their radioactivity was assayed in a gamma counter. For studies that
included anti–GP Ib
 
a
 
 blocking antibodies, the antibodies were
incubated with the immobilized glycocalicin for 15 min at room
temperature (each antibody at 40 
 
m
 
g/ml) before the addition of
the radiolabeled cells. Each experiment was performed in triplicate;
average counts from one representative experiment are reported.
 
Glycocalicin Inhibition of P-Selectin Antibody Binding to CHO-P.
 
CHO-P cells detached with EDTA were resuspended in 
 
a
 
–min-
imal essential medium (
 
a
 
-MEM; GIBCO BRL) containing 1%
BSA and aliquoted to a concentration of 2 
 
3 
 
10
 
6
 
 cells/ml. Puri-
fied glycocalicin or soybean trypsin inhibitor were then added to
the cell suspensions at various concentrations and shaken gently
for 15 min. Polyclonal anti–P-selectin antibody was then added
to each tube (final concentration, 2 
 
m
 
g/ml), and the cells were
incubated for an additional 45 min. The cells were then washed
twice in PBS, and FITC-conjugated goat anti–rabbit antibody
was added to a concentration of 8 
 
m
 
g/ml and incubated for 45
min. Antibody binding was then assessed by flow cytometry.
 
CHO Cell Aggregation.
 
CHO cells were labeled with mem-
brane dyes, CellTracker™ Orange (5-(and -6)-(((4 chloro-
methyl)benzoyl)amino)-tetramethylrhodamine) for CHO-P cells
and CellTracker™ Green (5-chloromethylfluorescein diacetate)
for CHO 
 
ab
 
IX and CHO 
 
b
 
IX (both dyes from Molecular
Probes, Inc.). For this, the cells were detached from the culture
dishes with 0.54 mM EDTA, centrifuged, and resuspended in
culture medium. The dyes were each added to the cell suspension
at 12 
 
m
 
M and incubated at 25
 
8
 
C for 60 min in the dark, with
gentle shaking. After labeling, the cells were washed twice in PBS
and resuspended in 
 
a
 
-MEM, 1% BSA to a concentration of 6 
 
3 
 
10
 
6
 
cells/ml. 500-
 
m
 
l aliquots of CHO-P cells were then mixed with
equal volumes of the other cell lines, and the mixture was shaken
on a table-top shaker at six cycles per second for 10 min. Hetero-
typic aggregates of green and orange cells were quantitated by
fluorescence microscopy. These experiments were also done with
CHO 
 
ab
 
IX cells pretreated with mocarhagin, a metalloprotease
from the venom of the South African spitting cobra, 
 
Naja mocam-
bique mocambique
 
. This protease selectively cleaves the GP Ib
 
a
 
NH
 
2 
 
terminus, including a region containing three sulfated ty-
rosine residues (16). Before the aggregation experiment, the
CHO 
 
ab
 
IX cells were incubated for 30 min with mocarhagin
(20 
 
m
 
g/ml) and then washed twice with PBS.
 
Preparation of Purified P-Selectin and P-Selectin Matrix.
 
Human
P-selectin was purified from outdated platelets as described previ-
ously (26). Detergent, Triton X-100, was removed from the
P-selectin sample immediately before use by passage through an
Extracti-Gel D column (Pierce Chemical Co.). To prepare the
P-selectin matrix, glass coverslips (No. 1, 24 
 
3
 
 50 mm; Corning
Glass Works) were coated with a solution containing 50 
 
m
 
g/ml
P-selectin for 4 h at 37
 
8
 
C followed by an additional 1-h incuba-
tion with PBS containing 1% BSA to block nonspecific binding
sites. The coated coverslips were then washed with 0.9% NaCl to
remove unbound P-selectin.
 
Preparation of Primary Cultures of Human Umbilical Vein Endothe-
lial Cells.
 
Human umbilical cords were collected and processed
 
for primary endothelial cell culture as described previously (27).
In brief, human umbilical cords were rinsed with PBS and then
treated with collagenase type II (10 
 
m
 
g/50 ml PBS; Worthington
Biochemical Corp.) for 40 min at room temperature. Enzymati-
cally dissociated human umbilical vein endothelial cells (HU-
VECs) were collected by centrifugation (10 min, 200 
 
g
 
) and then
resuspended in M199 medium (GIBCO BRL) supplemented
with 10% FBS and 1% glutamine. The cells were then plated
onto glass coverslips that had previously been coated with a 1%
gelatin solution for 30 min at 37
 
8
 
C. Cells were maintained at
378C with 5% CO2 and 95% humidity and reached confluence in
z4–5 d.
To induce surface expression of P-selectin, monolayers of con-
fluent HUVECs were treated with 25 mM histamine (Sigma
Chemical Co.) for 12 min at room temperature (27). Stimulated
cells were used immediately.
Parallel Plate Flow Chamber. The flow chamber system in-
cluded a parallel plate flow chamber, an inverted stage phase-con-
trast microscope (DIAPHOT-TMD; Nikon Inc.), and an image
recording system. The parallel plate flow chamber was composed
of a polycarbonate slab, a silicon gasket, and a glass coverslip held
together by vacuum in such a way that the coverslip forms the
bottom of the chamber. The coverslips were first coated with ei-
ther soluble P-selectin or a monolayer of HUVECs. The cham-
ber was maintained at 378C by an air curtain incubator attached
to the microscope. The wall shear stress was created by drawing
PBS through the chamber with a Harvard syringe pump and was
proportional to the fluid viscosity and flow rate and inversely
proportional to the width of the chamber and height of the gap
created by the gasket (28).
In studies of GP Ib-IX-V–mediated cell rolling on P-selectin,
0.6 ml of a suspension of CHO abIX, CHO bIX, L bIX, or L
abIXV cells (500,000 cells/ml) was injected into the chamber,
and the cells were incubated for 1 min with immobilized P-selec-
tin or 2 min with stimulated endothelial cells. At the end of the
incubation, PBS was perfused through the chamber at a flow rate
of 1.6 ml/min, generating a wall shear stress of 2 dynes/cm2
(shear rate z182/s). Cell rolling through a single view field was
recorded in real time for 4–6 min on videotape. The video data
were then analyzed off line using Inovision imaging software
(IC-300, Modular Image Processing Workstation; Inovision
Corp.) to quantify the number and velocities of the rolling cells
(27, 29). Cells considered to be rolling were those that translo-
cated over the matrix or HUVECs while maintaining constant
contact. The rolling velocity was defined as the distance a cell
traveled during a defined period (mm/s).
To examine platelet rolling on activated HUVECs, platelets pre-
pared as described below were resuspended to 2 3 108 cells/ml in
PBS with 1 mM CaCl2, 0.5 mM MgCl2, and 20% erythrocytes by
volume. The HUVECs were stimulated as above, and the platelet
suspension was allowed to incubate for 2 min at 378C before perfus-
ing the chamber with the platelet suspension at a flow rate of 1.6 ml/
min, generating a wall shear stress of 2 dynes/cm2 (shear rate z120/s).
Platelet Preparation.  Blood was drawn from healthy human
donors into 1/6 volume of acid citrate dextrose (85 mM Na3 ci-
trate, 111 mM dextrose, and 71 mM citric acid). The blood was
centrifuged at 170 g for 15 min at 258C to separate platelet-rich
plasma from erythrocytes and leukocytes. The platelets were then
pelleted from platelet-rich plasma by centrifugation at 800 g for
10 min at 258C. The platelets were then washed by suspension in
CGS buffer (13 mM sodium citrate, 30 mM glucose, and 120 mM
sodium chloride, pH 6.5), centrifuged again, and resuspended to
2 3 108 platelets/ml in PBS containing calcium and magnesium.806 Platelet GP Ib-IX-V Is a P-Selectin Receptor
All solutions except for the final resuspension buffer contained 1
mM prostaglandin E1 to prevent platelet activation.
Statistical Analysis.  The data were analyzed either by the
unpaired Student’s t test or by one-way analysis of variance
(ANOVA), depending on the nature of the data.
Results
CHO Cells Expressing P-Selectin Adhere to Immobilized Solu-
ble GP Iba (Glycocalicin) in a Calcium-independent Manner.
As a first step in determining if the GP Ib-IX-V complex
interacts with P-selectin, we examined the binding of
CHO-P cells to the soluble extracellular portion of human
GP Iba (called glycocalicin) immobilized on plastic. Gly-
cocalicin was purified from lysates of human platelets and
therefore contained all of the posttranslational modifica-
tions potentially required to constitute a platelet P-selectin
receptor. The binding of CHO-P cells to glycocalicin was
approximately fivefold greater than the binding of untrans-
fected cells (n 5 4, P , 0.001, Student’s t test), suggesting a
specific interaction between P-selectin and GP Iba (Fig. 1
A). We then tested the ability of different reagents to block
this interaction. The P-selectin interaction with PSGL-1 is
dependent on two structural modifications of PSGL-1: ty-
rosine sulfation within a negatively charged sequence at its
mature NH2 terminus and fucosylation, sialylation, and
core-2 branching of its O-linked carbohydrate. P-selectin
interacts with the carbohydrate motif through its C-type
lectin domain in a calcium-dependent fashion. We there-
fore tested whether EDTA would inhibit the interaction of
P-selectin with GP Iba. Surprisingly, and in contrast to the
interaction with PSGL-1, it did not (n 5 3, P 5 0.20, Stu-
dent’s t test; Fig. 1 B). However, antibodies against both
GP Iba and P-selectin did inhibit the interaction. Of the
GP Iba antibodies, the greatest inhibition of binding was
observed with SZ2 (z55% inhibition; n 5 3, P , 0.03,
one-way ANOVA, Dunnett’s method). This antibody has
been shown to recognize an epitope within the tyrosine-
sulfated anionic region of GP Iba (16), suggesting that this
region plays an important role in the recognition of P-selec-
tin. The other two GP Iba mAbs, WM23 and AK3, di-
rected against the GP Iba mucin core (18), inhibited bind-
ing to a lesser extent. Binding was also almost completely
inhibited by an affinity-purified rabbit polyclonal antibody
against P-selectin (n 5 3, P , 0.002, Student’s t test).
P-Selectin’s Interaction with GP Iba Mimics Its Interaction
with Heparin. Two findings indicated a potential similarity
between P-selectin’s interaction with GP Iba and its inter-
Figure 1. (A) Adhesion of CHO-P cells to glycocalicin. Glycocalicin, the soluble ex-
tracellular portion of GP Iba, was immobilized on the wells of plastic microtiter plates.
51Cr-labeled CHO-P cells or untransfected CHO cells were then incubated in the wells
under static conditions. After the wells were washed, the residual radioactivity was quan-
titated. (B) Inhibition of CHO-P adhesion to glycocalicin. The experiment was per-
formed as in A, except that the relevant inhibitor or control was either preincubated
with the bound glycocalicin (the anti-GP Iba antibodies) or incubated with the cells
during the adhesion assay. The adhesion is displayed as a percentage of the adhesion un-
der control conditions after subtracting the background adhesion of untransfected CHO
cells. Data are segregated into three sets. In the first set, the calcium dependence of the
interaction was assessed by performing the assay either in the presence or absence of 5
mM EDTA; the second set depicts the effects of GP Iba mAbs with an irrelevant anti-
body as a control; and the third set depicts the effect of an anti–P-selectin antibody, with
nonimmune rabbit IgG serving as the control. The antibodies used are 2C9, an anti–von
Willebrand factor antibody (control), and SZ2, WM23, and AK3, which are all directed
against GP Iba. SZ2 maps to the anionic sulfated region bounded by amino acid residues 276–282; WM23 and AK3 both bind within the mucin-like
macroglycopeptide region that lies between the anionic sulfated region and the plasma membrane. The anti-PS antibody is an affinity-purified rabbit
polyclonal antibody prepared against P-selectin purified from platelets. The experiment was performed three times in quadruplicate; data shown here are
derived from one representative experiment and are presented as mean 6 SE of the mean for that experiment. (C) Proteoglycan inhibition of CHO-P
adhesion to glycocalicin. Different proteoglycans were tested for their ability to inhibit the adhesion of CHO-P to glycocalicin. The experimental con-
ditions were as in A, except that the CHO-P cells were preincubated with the indicated proteoglycan at the following concentrations: 0.4 mg/ml fucoi-
din and chondroitin sulfate and 5 mg/ml heparin. As in B, the results are displayed as a percent of the adhesion of the control, untreated CHO-P cells,
after subtracting the background adhesion of untransfected CHO cells. Experiments were performed twice in quadruplicate; the results of one represen-
tative experiment are shown.807 Romo et al.
action with heparin: its calcium independence (17, 30) and
the involvement of the GP Iba anionic/tyrosine sulfated
region. This region of GP Iba contains three sulfated ty-
rosine residues (14, 16) and interacts with another of GP
Iba’s ligands, thrombin, through thrombin’s heparin-bind-
ing exosite (31, 32). We therefore studied the effect of
heparin and other proteoglycans on CHO-P adhesion to
glycocalicin. Heparin and the related proteoglycan fucoidin
both partially inhibited binding (n 5 3, P , 0.001, one-
way ANOVA, Tukey’s test; Fig. 1 C). In contrast, chon-
droitin sulfate, a control proteoglycan that does not block
the P-selectin–PSGL-1 interaction, similarly did not affect
the P-selectin–GP Iba interaction (P . 0.1).
Glycocalicin Blocks Antibody Binding to CHO-P Cells.
We next tested the ability of glycocalicin to interfere with
the binding to CHO-P cells of a polyclonal antibody
against human P-selectin. This antibody blocks the P-selec-
tin–PSGL-1 interaction (17) and, as shown in Fig. 1 B, also
blocks the adhesion of CHO-P to glycocalicin. Glycocali-
cin blocked antibody binding in a dose-dependent manner,
with a 50% inhibiting concentration (IC50) of z25 mg/ml
(n 5 3, P , 0.001, one-way ANOVA, Tukey’s test; Fig.
2). The results suggest that most of the binding determi-
nants for the polyclonal antibody lie within a restricted re-
gion of P-selectin close to the GP Iba binding site.
Posttranslational Core-2 Branching and a(1,3)-Fucosylation
Are Not Required for GP Iba Binding to P-Selectin. CHO cells
synthesize simple core-1 O-linked glycans (33) and are in-
capable of synthesizing PSGL-1 in a form competent to
bind P-selectin unless the appropriate carbohydrate-modi-
fying enzymes are also expressed (34). Thus, CHO cells
provide a good cell system to test whether carbohydrate
modification of GP Iba is required for its interaction with
P-selectin. The major carbohydrate structure of platelet GP
Iba (35–37) is very similar to that reported for PSGL-1 (3),
the only difference being the lack of an a(1,3)-fucosyl link-
age in GP Iba. We expressed the GP Ib-IX-V complex in
Figure 2. Inhibition of antibody binding to P-selectin. CHO-P cells
were incubated in increasing concentrations of glycocalicin or soybean
trypsin inhibitor before the addition of anti–P-selectin polyclonal anti-
body. The binding of the antibody was evaluated by flow cytometry after
incubation of the cells with an FITC-conjugated goat anti–rabbit second-
ary antibody. 100% binding is the binding in the absence of added pro-
tein. Glycocalicin inhibited antibody binding, with an IC50 of z25 mg/ml.
Soybean trypsin inhibitor had no effect. Values reported are averaged
from three experiments.
Figure 3. Assessment of the role of carbohydrate modification in the GP Iba–P-selectin interaction. (A) Expression of the HECA-452 epitope in
transfected cells. Cells transfected with cDNAs for FucT VII and C2GnT express the HECA-452 epitope. CHO bIX and CHO abIX cells were trans-
fected with either a FucT VII expression plasmid alone (F-VII) or together with the expression plasmid for C2GnT (C2). Sham-transfected CHO bIX
and CHO abIX served as negative controls. The appropriate carbohydrate modification was detected by cell surface binding of the antibody HECA-
452, which recognizes a FucT VII–dependent epitope. Binding was determined by flow cytometry after labeling the cells with an FITC-conjugated sec-
ondary antibody. The surface level is expressed as the geometric mean fluorescence of the cell population. HL60 cells served as positive controls for the
presence of the carbohydrate modification. (B) Heterotypic aggregation of CHO abIX and CHO-P cells. Aggregation of green-labeled CHO bIX or
CHO abIX cells with orange-labeled CHO-P cells was induced by coincubating the cells and shaking them on a table-top shaker. The ordinate repre-
sents the percentage of the green cells found in coaggregates with orange cells. (C) Inhibition of aggregation by mocarhagin. Before commencement of
the aggregation assay, CHO abIX cells were pretreated with mocarhagin, a cobra venom metalloprotease that selectively removes the GP Iba NH2 ter-
minus by cleavage between Glu282 and Asp283 (16). Adherence of the cells to CHO-P was then determined as in B. Values are depicted as percentages
of control binding after subtracting the background adhesion of CHO bIX cells.808 Platelet GP Ib-IX-V Is a P-Selectin Receptor
CHO cells alone, with FucT VII, or with both FucT VII
and the core-2 branching enzyme (C2GnT). We first as-
sessed whether the cells carry the necessary modification by
immunostaining with the antibody HECA-452, which rec-
ognizes FucT VII–dependent carbohydrate epitopes (19).
Whereas the untransfected cells demonstrated only a low
background fluorescence, all of the cell lines transfected
with both C2GnT and FucT VII demonstrated high levels
of the HECA-452 epitope (Fig. 3 A).
We then evaluated the ability of these cells to form het-
erotypic aggregates with cells expressing P-selectin. Cells
expressing the GP Ib-IX-V complex and its components
were fluorescently labeled with the membrane-permeable
dye CellTracker™ Green, and the CHO-P cells were la-
beled with CellTracker™ Orange. Equal quantities of the
two cell types were mixed and incubated with gentle shak-
ing, and the heterotypic aggregates containing both green
and orange cells were quantitated. Cells expressing GP Iba
demonstrated much greater heterotypic aggregation than
the control untransfected CHO cells or CHO cells express-
ing a partial complex lacking GP Iba (CHO bIX cells) (n 5
3, P , 0.01, one-way ANOVA, Tukey’s test; Fig. 3 B).
Expression of the carbohydrate-modifying enzymes led to
only a small further increment in the formation of hetero-
typic aggregates, indicating that carbohydrate modification
of GP Iba is less important to the interaction with P-selec-
tin than is the modification of PSGL-1. This finding is con-
sistent with the lack of calcium dependence of the interac-
tion. Calcium is required for the interaction of P-selectin
with certain carbohydrate ligands but not with sulfated gly-
cans such as heparin sulfate and fucoidin, which apparently
involves sulfated moieties (17, 26, 30).
The involvement of the GP Iba NH2 terminus in bind-
ing P-selectin was further implicated by studies with the
cobra venom metalloprotease mocarhagin (Fig. 3 C). This
protease removes the GP Iba NNH2 terminus to Glu282,
including much of the anionic sulfated region (16). Mocar-
hagin pretreatment of CHO abIX cells reduced hetero-
typic aggregation by z50% (n 5 3, P , 0.01, one-way
ANOVA, Tukey’s test).
Cells Expressing the GP Ib-IX-V Complex Roll on Immobi-
lized P-Selectin. The P-selectin–mediated rolling of plate-
lets on inflamed endothelium requires rapid on and off
rates. Thus, for the GP Ib-IX-V complex to constitute a
physiological counterreceptor for P-selectin, it should be
able to support a similar rolling interaction. To test this
possibility, we perfused cells expressing full or partial com-
plexes over coverslips coated with P-selectin in a parallel
plate flow chamber at a shear stress of 2 dynes/cm2. Cells
were observed to adhere to and roll on P-selectin (Fig. 4
A). The rolling interaction was independent of cell type, as
both CHO and L cells expressing the complex rolled at
similar velocities, whereas control cells lacking GP Iba did
not adhere or roll (Fig. 4 B).
Cells Expressing the GP Ib-IX Complex and Platelets Roll on
Histamine-activated Endothelium. We next tested whether
the GP Ib-IX-V complex could also support cell rolling on
stimulated endothelial cells. Endothelial cells were collected
from human umbilical veins and grown directly on gelatin-
coated coverslips. When confluent, they were activated
with 25 mM histamine and the coverslip was immediately
placed in the parallel plate flow chamber. CHO abIX cells
were then perfused over the monolayer. Negative controls
were CHO abIX cells perfused over untreated endothe-
lium and CHO bIX cells perfused over activated endothe-
lium. CHO abIX cells adhered to and rolled on the acti-
Figure 4. Rolling of GP Iba–expressing cells on immobilized P-selec-
tin. (A) CHO cells expressing either the GP Ib-IX complex or only
GP Ibb and GP IX were allowed to settle onto coverslips coated with
P-selectin in parallel plate flow chambers. After 1 min, the chambers were
perfused with PBS at a constant flow rate to generate a shear stress of 2
dynes/cm2. The top panels show cells before application of shear stress,
and the bottom panels show the same region during perfusion. The im-
ages in the bottom panels represent a compilation of a series of frames
taken over 2 s. The linear blurs represent those cells that have adhered to
the matrix and are rolling on it. (B) Velocity and numbers of cells rolling
on immobilized P-selectin. Both L and CHO cells were studied, with no
significant differences noted between the two in either velocity or num-
ber of rolling cells. The presence of GP V also did not influence rolling.
No velocity is given for cells lacking GP Iba because no rolling cells were
observed. The number of cells rolling per field were counted during a
3-min interval from the start of the perfusion.809 Romo et al.
vated endothelial monolayer but not on the unstimulated
endothelium (Fig. 5). A low level of CHO bIX adhesion
to activated endothelium was noted, but this did not ex-
ceed the level of adhesion of these cells to the unstimulated
endothelium. Adhesion of the CHO abIX cells was blocked
by the polyclonal antibody against P-selectin (Fig. 5 and
Table I).
As a final, and more physiological, test of the GP Ib-IX-V
complex–P-selectin interaction, we studied the effects of
antibodies to GP Iba and P-selectin on platelet rolling on
stimulated endothelium (Fig. 6). Platelet suspensions (2 3
108 platelets/ml and 20% washed erythrocytes in PBS con-
taining calcium and magnesium) were perfused over hista-
mine-stimulated endothelium either without treatment or
in the presence of antibodies against GP Iba (SZ2 and
AK2, alone and in combination), P-selectin (polyclonal
anti–P-selectin), or von Willebrand factor (6G1). The
number of platelets rolling was much greater on activated
than on unactivated endothelium. Treatment with the two
GP Iba mAbs markedly inhibited adhesion and rolling of
the platelets, with AK2 being a more potent inhibitor, re-
ducing the number of rolling cells to the level seen on un-
stimulated endothelial cells. (We did not use AK2 in the
experiments examining CHO-P adhesion to glycocalicin
because it does not bind to immobilized glycocalicin.)
Anti–P-selectin decreased platelet rolling to levels even be-
low those of the unstimulated endothelial cells, suggesting a
background level of endothelial cell activation. The anti–
von Willebrand factor mAb, 6G1, did not significantly af-
fect platelet rolling.
Discussion
Here we demonstrate a specific interaction between a
platelet adhesion receptor, the GP Ib-IX-V complex, and
P-selectin. This interaction represents a potential new para-
digm for platelet adhesion, where the same receptor (GP
Ib-IX-V) can support platelet adhesion to endothelial cells
under the appropriate conditions of endothelial activation
and to the subendothelial matrix when the endothelial cells
have been removed by injury. Several interesting parallels
exist between GP Iba and PSGL-1 as cell adhesion recep-
tors. Both are membrane mucins with elongated structures
formed by the presence of a heavily O-glycosylated region
rich in threonine, serine, and proline residues (38, 39). In
both receptors, this mucin-like region separates the ligand-
binding region from the plasma membrane (40, 41), and in
both it contains tandemly repeated sequences that account
for polymorphism in the human population because of
variable numbers of the tandem repeats (42, 43). The ma-
jor carbohydrate structures of the two receptors are very
similar, with only a fucose in a(1,3) linkage in the major
PSGL-1 carbohydrate chain differentiating it from the ma-
jor carbohydrate species of GP Iba. Furthermore, both
receptors contain a highly acidic region with sulfated
tyrosines that is important for ligand binding and lies im-
mediately NH2-terminal to the mucin-like region (4–7,
Figure 5. Adhesion of GP
Iba–expressing cells to hista-
mine-activated  endothelium.
HUVEC monolayers were acti-
vated by treatment with 25 mM
histamine, and the coverslips
were immediately placed in the
parallel plate flow chamber. Cells
were allowed to settle for 2 min,
and the chambers were then per-
fused with PBS.
Table I. Number of CHO Cells Rolling on Human Umbilical 
Vein Endothelium
Cell lines Unstimulated
Stimulated
No antibody Anti–P-selectin
CHO abIX 7.60 6 1.33 33.30 6 3.62* 8.00 6 2.07
CHO bIX N/A 4.66 6 2.03 N/A
*Student’s t test, P , 0.01.
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14–16). The major ligands for both receptors (von Wille-
brand factor and P-selectin) are synthesized only in mega-
karyocytes and endothelial cells and are stored in the same
subcellular compartments, the a-granules of platelets and
megakaryocytes and the Weibel-Palade bodies of endothe-
lial cells.
Despite all of these similarities, the interactions of the
two mucins with P-selectin are quite different. Whereas
PSGL-1 requires carbohydrate modification with core-2
branching and a(1,3)-fucosylation and the presence of cal-
cium for its interaction with P-selectin, GP Iba requires
neither. This lack of a requirement for carbohydrate modi-
fication is consistent with the findings of Frenette et al. (8)
that the platelet P-selectin counterreceptor does not re-
quire modification by FucTs for function.
The different carbohydrate requirements of the two
P-selectin counterreceptors may not be absolute but rather
may represent a difference in the relative importance of the
two P-selectin binding determinants (carbohydrates and
sulfated tyrosines). GP Iba does not contain the fucosylated
moiety that is so vital for PSGL-1; on the other hand, its
anionic region has a much higher concentration of negative
charge than does the analogous region of PSGL-1, as well
as three tyrosines that are fully sulfated (14, 16). This region
of GP Iba is known to bind tightly to thrombin and does
so by interacting with the same region of thrombin that
binds heparin (31, 32). Thus, the anionic sulfated region of
GP Iba, with its high negative charge and sulfate groups,
appears to resemble heparin. Several lines of evidence point
to the importance of this heparin-like region of GP Iba in
the interaction with P-selectin. First, the calcium indepen-
dence of the interaction resembles the interaction of P-selectin
with heparin, as does the pattern of blockade with heparin
and fucoidin, but not with chondroitin sulfate (17). Second,
the interaction is inhibited by SZ2, an mAb that binds within
the region and also partially blocks botrocetin-induced von
Willebrand factor binding, a phenomenon known to be sen-
sitive to the removal of tyrosine sulfates (15, 16). Finally,
mocarhagin, the cobra venom metalloprotease that re-
moves most of the heparin-like region, also inhibits bind-
ing. Thus, the GP Iba–P-selectin interaction is almost com-
pletely independent of carbohydrate, although the failure of
SZ2 or mocarhagin to fully inhibit the interaction suggests
that carbohydrate may have a minor role.
The possible involvement of other regions of GP Iba in
the interaction is also suggested by the inhibition by the
mAb AK2 of platelet rolling on stimulated endothelial cells.
This antibody binds within the leucine-rich repeats of GP
Iba (16). However, because the three-dimensional rela-
tionship of the leucine-rich repeats with the sulfated region
in three dimensions is not known, we cannot definitively
make a case for the involvement of the leucine-rich repeats
in the interaction. The potential involvement of all of the
regions of GP Iba will have to await more definitive stud-
ies with mutant polypeptides.
The adhesion of platelets to regions of vessel wall injury
mediated by von Willebrand factor can occur at very high
shear stresses, approaching 100 dynes/cm2. The interaction
between platelets and endothelium, on the other hand,
seems to occur at much lower shear stresses, although
evidence exists that platelets can interact with endothelium
at shear stresses above those able to support the interaction
of leukocytes with the endothelium (44). The studies re-
ported here were carried out at venular shear stresses and
do not address the possibility that the GP Iba–P-selectin
interaction may be able to support platelet rolling at shear
stresses much higher than those that support leukocyte
rolling.
The demonstration of an abundant receptor on the
platelet surface for P-selectin brings into sharp focus the
potential roles of this receptor–counterreceptor interaction
in both physiological and pathological conditions. During
hemostasis, the interface between the GP Ib-IX-V com-
plex and P-selectin may be important in the interaction be-
tween activated and unactivated platelets. Activated plate-
lets with surface-exposed P-selectin could associate with
and activate previously unactivated platelets, thus providing
a mechanism for propagation of platelet thrombi. Failure of
Figure 6. Platelet rolling on activated endothe-
lium. Platelet suspensions (600 ml at 2 3 108 plate-
lets/ml in buffer containing 20% washed erythro-
cytes) were incubated with HUVEC monolayers
(prepared as for Fig. 5) for 2 min and then perfused
over the monolayer for an additional 3 min. Roll-
ing platelets were counted per 603 field over the
3-min perfusion. The experiment was performed
three times (except for the 6G1 inhibition, which
was only performed once), and values are expressed
as percentages of the numbers of cells rolling on the
histamine-stimulated endothelium. 100% for the
stimulated, untreated cells ranged from 16 to 21
cells/min. The decrease in rolling in cells treated
with either GP Iba or P-selectin antibodies was
statistically significant (n 5 3, P , 0.001, one-way
ANOVA, Tukey’s test).811 Romo et al.
this mechanism could explain the mild bleeding diathesis of
P-selectin–deficient mice (45) and could contribute to the
bleeding tendency in patients with Bernard-Soulier syn-
drome, the genetic disorder resulting from deficiency of
the GP Ib-IX-V complex (46). Nevertheless, this mecha-
nism is likely to be only of secondary importance, as no de-
fect in aggregation has been found in the platelets of pa-
tients with Bernard-Soulier syndrome (although a subtle
defect might not be detected by conventional methods of
performing aggregation).
Under certain circumstances, platelets may help neutro-
phils and other white cells to exit the vasculature by pro-
viding an additional ligand for recognizing activated endo-
thelial cells. Such a role has been demonstrated for platelets
in lymphocyte trafficking, where activated platelets bound
to the lymphocytes can provide a ligand (P-selectin) for the
endothelial addressins of lymph nodes (47). Platelets inter-
acting with activated endothelium may themselves become
activated, releasing factors that may influence the behaviors
of both the endothelial cells and underlying smooth muscle
cells. When such a process is unchecked, such as during
sepsis, the platelets may contribute to the deleterious effects
of the underlying condition. In this regard, recent findings
suggest that activated platelets also form stable attachments
with endothelial cells mediated in part by other platelet GP
receptors, such as the integrin GP IIb-IIIa (48). At this
point, however, the potential biological consequences of
platelet interaction with endothelium are speculative. Nev-
ertheless, with the demonstration of such a specific interac-
tion involving endothelial selectins (9) and the current
identification of a platelet receptor for these selectins, the
endothelium can no longer be considered refractory to the
overtures of the platelet.
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